Mitchell Lawrence Jones - 06 Nov 2023 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Role
Chief Medical Officer
Signature
/s/ Mitchell Jones
Issuer symbol
PALI
Transactions as of
06 Nov 2023
Net transactions value
-$878
Form type
4
Filing time
08 Nov 2023, 17:01:05 UTC
Previous filing
13 Sep 2023
Next filing
24 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PALI Common Stock, par value $0.01 Options Exercise $0 +4,556 $0.000000 4,556 06 Nov 2023 Direct F1
transaction PALI Common Stock, par value $0.01 Tax liability $878 -1,630 -36% $0.5389 2,926 07 Nov 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PALI Restricted Stock Units Options Exercise -4,556 -8.3% 50,144 06 Nov 2023 Common Stock 4,556 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units.
F2 Represents shares sold on behalf of Reporting Person to satisfy tax requirements related to the vesting of the restricted stock units.
F3 This restricted stock unit was granted on September 5, 2023, and 4,556 restricted stock units subject to the award vested on November 6, 2023, and an additional 50,144 restricted stock units will vest in equal installments over the eleven (11) quarterly periods thereafter, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting.
F4 Each restricted stock unit represents the right to receive, at settlement, one share of common stock.